Silexion Therapeutics effects 1-for-15 reverse stock split, adjusts warrant terms

Silexion Therapeutics Corp

Reverse split effective after close July 28; trading on split-adjusted basis July 29 under same ticker SLXN.
Authorized shares unchanged at 1,481,482; par value increased from $0.0009 to $0.0135 per share.
Each warrant now exercisable for 1/15th of a share; exercise price adjusted to $1,552.50 per whole share.
No fractional shares will be issued; fractional interests rounded up to nearest whole share.
CUSIP for ordinary shares changed to G1281K 130; warrant CUSIP remains G1281K 114.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Silexion Therapeutics Corp: Filed a certificate with the Cayman Islands Companies Registry to amend the Amended and Restated Memorandum of Association, effecting a 1-for-15 reverse share split. Authorized share capital remains $20,000 but now consists of 1,481,482 ordinary shares; par value increased from $0.0009 to $0.0135 pe (effective 2025-07-28).

Change: charter amendment
Effective: 2025-07-28

Exact text from the filing

On July 28, 2025, the Company’s Board of Directors, acting pursuant to that approval by the Company’s shareholders, effected the Reverse Share Split following the close of trading on the Nasdaq Capital Market through the filing of a certificate with the Companies Registry of the Cayman Islands that served as an effective amendment to the Company’s Amended and Restated Memorandum of Association (the “ Memorandum Amendment ”).

View on SEC.gov

51 governance changes filed in the last 30 days. Browse all governance changes →

Silexion Therapeutics Corp filing history →

Source: SEC EDGAR

accession 0001178913-25-002515

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.